Skip to main navigation Skip to search Skip to main content

Intensity-modulated radiotherapy for rectal cancer in the UK in 2020

  • C. R. Hanna*
  • , F. Slevin
  • , A. Appelt
  • , M. Beavon
  • , R. Adams
  • , C. Arthur
  • , M. Beasley
  • , A. Duffton
  • , A. Gilbert
  • , S. Gollins
  • , M. Harrison
  • , M. A. Hawkins
  • , K. Laws
  • , S. O'Cathail
  • , P. Porcu
  • , M. Robinson
  • , D. Sebag-Montefiore
  • , M. Teo
  • , S. Teoh
  • , R. Muirhead
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Downloads (Pure)

Abstract

Aims: Preoperative (chemo)radiotherapy followed by total mesorectal excision is the current standard of care for patients with locally advanced rectal cancer. The use of intensity-modulated radiotherapy (IMRT) for rectal cancer is increasing in the UK. However, the extent of IMRT implementation and current practice was not previously known. A national survey was commissioned to investigate the landscape of IMRT use for rectal cancer and to inform the development of national rectal cancer IMRT guidance. 

Materials and methods: A web-based survey was developed by the National Rectal Cancer IMRT Guidance working group in collaboration with the Royal College of Radiologists and disseminated to all UK radiotherapy centres. The survey enquired about the implementation of IMRT with a focus on the following aspects of the workflow: dose fractionation schedules and use of a boost; pre-treatment preparation and simulation; target volume/organ at risk definition; treatment planning and treatment verification. A descriptive statistical analysis was carried out. 

Results: In total, 44 of 63 centres (70%) responded to the survey; 30/44 (68%) and 36/44 (82%) centres currently use IMRT to treat all patients and selected patients with rectal cancer, respectively. There was general agreement concerning several aspects of the IMRT workflow, including patient positioning, use of intravenous contrast and bladder protocols. Greater variation in practice was identified regarding rectal protocols; use of a boost to primary/nodal disease; target volume delineation; organ at risk delineation and dose constraints and treatment verification. Delineation of individual small bowel loops and daily volumetric treatment verification were considered potentially feasible by most centres. 

Conclusion: This survey identified that IMRT is already used to treat rectal cancer in many UK radiotherapy centres, but there is heterogeneity between centres in its implementation and practice. These results have been a valuable aid in framing the recommendations within the new National Rectal Cancer IMRT Guidance.

Original languageEnglish
Pages (from-to)214-223
Number of pages10
JournalClinical Oncology
Volume33
Issue number4
Early online date07 Jan 2021
DOIs
Publication statusPublished - Apr 2021
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • IMRT
  • intensity-modulated radiotherapy
  • neoplasm
  • rectal cancer
  • survey

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Intensity-modulated radiotherapy for rectal cancer in the UK in 2020'. Together they form a unique fingerprint.

Cite this